US 2015/0306070 A1 · USE OF MALEIMIDE DERIVATIVES FOR PREVENTING AND TREATING LEUKEMIA

Abstract

The present invention is related to a compound of formula (I): a pharmaceutically acceptable salt thereof, a hydrate thereof, a solvate thereof, a metabolite thereof or a prodrug thereof; for use in a method for the treatment and/or prevention of leukemia, wherein X is selected from the group consisting of N—R1, O and S; R1 is selected from the group consisting of alkyl, cycloalkyl, aryl, arylalkyl and hydrogen; R2 is selected from the group consisting of indolyl, substituted indolyl, azaindolyl and substituted azaindolyl; and R3 is selected from the group consisting of aryl, substituted aryl, unsubstituted heteroaryl, heterocyclyl and substituted heterocyclyl.

Claims89

Dependent claims

A compound of formula (I):

a pharmaceutically acceptable salt thereof, a hydrate thereof, a solvate thereof, a metabolite thereof or a prodrug thereof;
for use in a method for the treatment and/or prevention of leukemia,
wherein
X is selected from the group consisting of N—R1, O and S;
R1 is selected from the group consisting of alkyl, cycloalkyl, aryl, arylalkyl and hydrogen;
R2 is selected from the group consisting of indolyl, substituted indolyl, azaindolyl and substituted azaindolyl;
and
R3 is selected from the group consisting of aryl, substituted aryl, unsubstituted heteroaryl, heterocyclyl and substituted heterocyclyl.

5 more elements

A compound of formula (I):

a pharmaceutically acceptable salt thereof, a hydrate thereof, a solvate thereof, a metabolite thereof or a prodrug thereof;
wherein
X is selected from the group consisting of N—R1, O and S;
R1 is selected from the group consisting of alkyl, cycloalkyl, aryl, arylalkyl and hydrogen;
R2 is selected from the group consisting of indolyl, substituted indolyl, azaindolyl and substituted azaindolyl;
and
R3 is selected from the group consisting of aryl, substituted aryl, unsubstituted heteroaryl, heterocyclyl and substituted heterocyclyl.

4 more elements

Dependencies are inferred from the claim text.

Facts

Application

14/650,939Filed 10 Dec 2013

Priority

EP 12008229.210 Dec 2012

Published

29 Oct 2015

Term ends

Not estimatedThe source records don’t support an estimate.

Classification21 codes

A61K 31/404
Condensed with carbocyclic rings, e.g. carbazole: indoles, e.g. pindolol
A61K 31/203
Having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids: retinoic acids ; Salts thereof
A61K 31/437
Ortho- or peri-condensed with heterocyclic ring systems: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring…
A61K 31/44
Having six-membered rings with one nitrogen as the only ring hetero atom: non condensed pyridines; Hydrogenated derivatives thereof

Use of maleimide derivatives for preventing and treating leukemia

Life of this patent

Use of maleimide derivatives for preventing and treating leukemia

Life of this patent

Abstract

Claims89